The 8R-70CAR-T cells demonstrated enhanced migratory and proliferative capacities resulting in complete tumor regression of advanced-stage tumors, such as GBM, ovarian, and pancreatic cancers, compared to the nonmodified CD70-CAR-T cells.11 This research is culminating in a phase I clinical trial involving 8R-70CAR T cells for newly diagnosed GBM (NCT05353530), which is recruiting now at University of Florida.68 This evidence concerns the gene CD70 and pancreatic neoplasm.